节段性斑状色素沉着:新基因与新临床意义
这项前瞻性队列研究纳入50名节段性斑状色素沉着患儿,对42名患儿皮损行高深度二代测序以检测嵌合变异。结果发现3例GNAS嵌合变异,另5例发现新遗传病因,包括NRAS、BRAF、PTPN11嵌合变异及5p染色体嵌合拷贝数变异,血液中均检测不到。不同遗传病因对患者管理有不同意义,提示即使临床健康也应进行基因分型。
要点
- 节段性斑状色素沉着除GNAS嵌合外,还存在NRAS、BRAF、PTPN11嵌合变异及5p染色体嵌合拷贝数变异等新病因。
- GNAS变异需监测其他系统,NRAS/BRAF/PTPN11需关注黑色素瘤风险及遗传咨询。
- 皮损基因检测对节段性斑状色素沉着患者的管理有重要意义,即使临床健康也应考虑。
核心结论
- 节段性斑状色素沉着存在多种新遗传病因,包括NRAS、BRAF、PTPN11嵌合变异及5p染色体嵌合拷贝数变异,血液中均检测不到。
- 不同遗传病因对患者管理有不同意义,包括系统监测、黑色素瘤 awareness 及遗传咨询。
研究设计与样本
- 前瞻性队列研究,连续招募50名儿童,进行表型和基因型研究,历时15年。
- 对42名儿童皮损行高深度二代测序,生物信息学分析优化嵌合变异检测。
主要发现
- 3例患者检出GNAS嵌合变异,就诊时均无其他异常,但其中1例在随访期间出现内分泌并发症。
- 另5例患者发现新遗传病因:NRAS嵌合变异2例,BRAF嵌合变异1例,PTPN11嵌合变异1例,5p染色体嵌合拷贝数变异1例,血液中均检测不到。
- 多数病例变异等位基因频率极低,可能反映斑状皮损全皮肤活检中变异细胞极少,即使当前灵敏度下仍可能遗漏致病变异。
临床怎么用
- 检出GNAS变异需监测和检查其他系统。
- 检出NRAS/BRAF/PTPN11变异需讨论黑色素瘤 awareness 及将变异作为胚系疾病传给后代的可能性。
- 染色体异常可能涉及多个临床领域。
- 节段性斑状色素沉着患者即使临床健康也应进行基因分型。
局限性
- 多数病例变异等位基因频率极低,即使当前灵敏度下仍可能遗漏致病变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Segmental macular hyperpigmentation (SMH) is macular hyperpigmentation in a defined developmental pattern, presenting at birth or in the early years. The only known cause of this phenotype has been mosaicism of gene GNAS, as part of McCune-Albright syndrome. It is unknown how often GNAS mosaicism is the cause of SMH presenting to dermatology or whether there are other genetic causes for the phenotype with different clinical implications. OBJECTIVES: To investigate the genetic causes of SMH and the natural history of the condition. METHODS: A prospective cohort of 50 children were recruited consecutively for phenotypic and genotypic studies over a period of 15 years. High-depth next-generation sequencing of affected skin with bioinformatic analysis optimized for mosaic variant detection was performed in 42 children. RESULTS: Three patients with mosaic GNAS variants were identified, all otherwise well at presentation, but one of whom went on to develop endocrine complications in the follow-up period. Importantly, in a further five patients, new genetic causes were identified. These were pathogenic mosaic variants in single genes (NRAS, n = 2; BRAF, n = 1; PTPN11, n = 1) and a mosaic chromosomal copy number variant (chromosome 5p gain, n = 1), all undetectable in blood. In most cases, the variant allele frequency was extremely low, probably reflecting the very few variant cells in a whole skin biopsy of a macular lesion, and it is possible that causative variants in tested genes are still being missed, even at current sensitivities. CONCLUSIONS: The discovery of these highly disparate genetic causes has important implications for personalized patient management. Specifically, detection of GNAS variants will involve monitoring and investigation of other systems; NRAS/BRAF/PTPN11 will involve discussion of melanoma awareness and the potential of passing on variants as germline diseases to future offspring; and chromosomal abnormalities may have implications in multiple clinical areas. Our findings multiply the known causes of SMH and reveal the importance of genotyping patients presenting to dermatology, even when clinically well. ‘Segmental macular hyperpigmentation’ is a type of large, flat, pigmented birthmark. Only one cause of these birthmarks is already known. We studied 50 children in the UK with these birthmarks to try to find new causes. We collected information from these patients and looked for faulty genes inside the birthmark. By using tiny samples of their skin, we found four new genetic causes of these birthmarks. The different genetic causes affect how people with these birthmarks should be checked, tested and counselled. One example of this is that some of the genetic causes of the birthmarks could potentially be passed on to any children they may have. Another example is that some of the genetic causes may increase the risk of skin cancer in the birthmark. Our findings highlight how important it is to do genetic testing on these birthmarks, even if the person is otherwise well.
引用
- Kinsler VA, Knöpfel N, Polubothu S, et al. Segmental macular hyperpigmentation: new genes, new clinical implications. Br J Dermatol. 2025. PMID: 40644320. doi:10.1093/bjd/ljaf254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。